Hematuria and Crystalluria after High-Dose 6-Mercaptopurine Administration

Abstract

DESPITE the clinical use of 6-mercaptopurine (6-MP) for 18 years, acute genitourinary toxicity seems not to have been reported, although hematologic, gastrointestinal, hepatic and, uncommonly, dermatologic toxicity have been seen.1 The nine children with acute leukemia recently seen on the Leukemia Service, National Cancer Institute, described below experienced hematuria and crystalluria in association with high-dosage parenteral 6-MP administration.Case ReportsHematuria was first noted in this group of patients in December, 1970, and January, 1971, when five children had grossly bloody urine while receiving POMP combination therapy (vincristine, 2.0 mg per square meter, on the first day, and prednisolone, 1000 . . .